

Attorney Docket No. P33089

---

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB2003/003316	30 July 2003	31 July 2002

---

TITLE OF INVENTION

FUSED HETEROARYL DERIVATIVES FOR USE AS P38 INHIBITORS (amended)

---

APPLICANT(S) FOR DO/US

Richard M. ANGELL, Ian R. BALDWIN, Paul BAMBOROUGH, Nigel Marc DEBOECK,  
Timothy LONGSTAFF, Stephen SWANSON

---

FILING OF AN INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ [X] A copy of the International Search Report, which issued on International Application No. PCT/GB2003/003316 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

☐ [ ] Copies of references not listed on the International Search Report are enclosed.

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The Examiner's attention is drawn to the following table in which various co-pending applications and publications are presented. Copies of the WO publications and pending claims in each application will be forwarded after receipt of the US serial number is obtained in this application to avoid any confusion. If the Examiner would like copies of any of these in the meanwhile, please contact the undersigned at the number indicated below.

Int'l App. No: PCT/GB2003/003316

Int'l Filing Date: 3 July 2003

Information Disclosure Statement

D. Referred to PTO 31 JAN 2005

- 2 -

PCT/GB03/00554 USSN 10/503,968	WO 03/068747
PCT/GB03/01834 USSN 10/513,095	WO 03/093248
PCT/GB01/03783 USSN 10/362,146	WO 02/16359 US 2004-0053942
PCT/EP02/11569 USSN 10/492,713	WO 03/032986
PCT/EP02/11570 USSN 10/492,714	WO 03/032970
PCT/EP02/11571 USSN 10/492,715	WO 03/033457
PCT/EP02/11572 USSN 10/492,697	WO 03/033483
PCT/EP02/11573 USSN 10/492,699	WO 03/032980
PCT/EP02/11574 USSN 10/492,711	WO 03/033482
PCT/EP02/11575 USSN 10/492,497	WO 03/032987
PCT/EP02/11576 USSN 10/492,605	WO 03/032971
PCT/EP02/11577 USSN 10/492,698	WO 03/032972

This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Theodore R. Furman  
Attorney for Applicants  
Registration No. 30,942

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-6857  
Facsimile (610) 270-5090

33089\ids

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P33089	INTERNATIONAL APPLICATION NO. PCT/GB03/03316
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Angell, et al.	
		FILING DATE Herewith	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US2004-0053942					

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 95/15954	15 Jun 95	WIPO				
	WO 94/15920	21 Jul 94	WIPO				
	WO 03/033482	24 Apr 03	WIPO				
	WO 03/032987	24 Apr 03	WIPO				
	WO 03/032986	24 Apr 03	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Boehm & Adams, Expert Opinion on Therapeutic Patents, Vol. 10 (1) pgs 25-37 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## ABSTRACT OF THE DISCLOSURE

Compounds of formula (I):



(I)

wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.